|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopez-Beltran A, Carrasco JC, Cheng L,
Scarpelli M, Kirkali Z and Montironi R: 2009 update on the
classification of renal epithelial tumors in adults. Int J Urol.
16:432–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lopez-Beltran A, Scarpelli M, Montironi R
and Kirkali Z: 2004 WHO classification of the renal tumors of the
adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brekken RA and Sage EH: SPARC, a
matricellular protein: At the crossroads of cell-matrix
communication. Matrix Biol. 19:816–827. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vannahme C, Smyth N, Miosge N, Gösling S,
Frie C, Paulsson M, Maurer P and Hartmann U: Characterization of
SMOC-1, a novel modular calcium-binding protein in basement
membranes. J Biol Chem. 277:37977–37986. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vannahme C, Gösling S, Paulsson M, Maurer
P and Hartmann U: Characterization of SMOC-2, a modular
extracellular calcium-binding protein. Biochem J. 373:805–814.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan Q and Sage EH: SPARC, a matricellular
glycoprotein with important biological functions. J Histochem
Cytochem. 47:1495–1506. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and
Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are
prognosis-related in colorectal cancer. World J Gastroenterol.
17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taylor BS, Schultz N, Hieronymus H, et al:
Integrative genomic profiling of human prostate cancer. Cancer
Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chandran UR, Ma C, Dhir R, Bisceglia M,
Lyons-Weiler M, Liang W, Michalopoulos G, Becich M and Monzon FA:
Gene expression profiles of prostate cancer reveal involvement of
multiple molecular pathways in the metastatic process. BMC Cancer.
7:642007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hurley PJ, Marchionni L, Simons BW, Ross
AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z,
et al: Secreted protein, acidic and rich in cysteine-like 1
(SPARCL1) is down regulated in aggressive prostate cancers and is
prognostic for poor clinical outcome. Proc Natl Acad Sci USA.
109:14977–14982. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bendik I, Schraml P and Ludwig CU:
Characterization of MAST9/Hevin, a SPARC-like protein, that is
down-regulated in non-small cell lung cancer. Cancer Res.
58:626–629. 1998.PubMed/NCBI
|
|
14
|
Nelson PS, Plymate SR, Wang K, True LD,
Ware JL, Gan L, Liu AY and Hood L: Hevin, an antiadhesive
extracellular matrix protein, is down-regulated in metastatic
prostate adenocarcinoma. Cancer Res. 58:232–236. 1998.PubMed/NCBI
|
|
15
|
Zaravinos A, Lambrou GI, Boulalas I,
Delakas D and Spandidos DA: Identification of common differentially
expressed genes in urinary bladder cancer. PLoS One. 6:e181352011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esposito I, Kayed H, Keleg S, Giese T,
Sage EH, Schirmacher P, Friess H and Kleeff J: Tumor-suppressor
function of SPARC-like protein 1/Hevin in pancreatic cancer.
Neoplasia. 9:8–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann
BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, et al:
SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol.
7:1019–1030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hurley PJ, Hughes RM, Simons BW, et al:
Androgen-Regulated SPARCL1 in the tumor microenvironment inhibits
metastatic progression. Cancer Res. 75:4322–4334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sivaraman VS, Wang H, Nuovo GJ and Malbon
CC: Hyperexpression of mitogen-activated protein kinase in human
breast cancer. J Clin Invest. 99:1478–1483. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoshino R, Chatani Y, Yamori T, Tsuruo T,
Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno
M: Constitutive activation of the 41-/43-kDa mitogen-activated
protein kinase signaling pathway in human tumors. Oncogene.
18:813–822. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eliceiri BP, Klemke R, Strömblad S and
Cheresh DA: Integrin alphavbeta3 requirement for sustained
mitogen-activated protein kinase activity during angiogenesis. J
Cell Bio. 140:1255–1263. 1998. View Article : Google Scholar
|
|
22
|
Mandell JW, Hussaini IM, Zecevic M, Weber
MJ and VandenBerg SR: In situ visualization of intratumor growth
factor signaling: Immunohistochemical localization of activated
ERK/MAP kinase in glial neoplasms. Am J Pathol. 153:1411–1423.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Røe OD, Szulkin A, Anderssen E, Flatberg
A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K and Sundstrøm SH:
Molecular resistance fingerprint of pemetrexed and platinum in a
long-term survivor of mesothelioma. PLoS One. 7:e405212012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang RL, Yuan Y, Tu J, Zou GM and Li Q:
Opposing TNF-α/IL-1β- and BMP-2-activated MAPK signaling pathways
converge on Runx2 to regulate BMP-2-induced osteoblastic
differentiation. Cell Death Dis. 5:e11872014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo C, Yang XG, Wang F and Ma XY: IL-1α
induces apoptosis and inhibits the osteoblast differentiation of
MC3T3-E1 cells through the JNK and p38 MAPK pathways. Int J Mol
Med. 38:319–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kyosseva SV: Targeting MAPK signaling in
Age-related macular degeneration. Ophthalmol Eye Dis. 8:23–30.
2016.PubMed/NCBI
|
|
27
|
Lim W, Jeong M, Bazer FW and Song G:
Coumestrol inhibits proliferation and migration of prostate cancer
cells by regulating AKT ERK1/2, and JNK MAPK cell signaling
cascades. J Cell Physiol. 232:862–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Gao C, Zhang Y, Gao J, Teng F,
Tian W, Yang W, Yan Y and Xue F: Visfatin stimulates endometrial
cancer cell proliferation via activation of PI3K/Akt and
MAPK/ERK1/2 signalling pathways. Gynecol Oncol. 143:168–178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang A, Fan H, Zhao Y, Zha X, Zhang H, Hu
Z and Tu P: Huaier aqueous extract inhibits proliferation and
metastasis of tuberous sclerosis complex cell models through
downregulation of JAK2/STAT3 and MAPK signaling pathways. Oncol
Rep. 36:1491–1498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yue X, Wu M, Jiang H, Hao J, Zhao Q, Zhu
Q, Saren G, Zhang Y and Zhang X: Endothelial lipase is upregulated
by interleukin-6 partly via the p38 MAPK and p65 NF-kB signaling
pathways. Mol Med Rep. 14:1979–1985. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koyani CN, Kitz K, Rossmann C, Bernhart E,
Huber E, Trummer C, Windischhofer W, Sattler W and Malle E:
Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63
osteosarcoma cells against 15d-PGJ2-mediated cell death. Biochem
Pharmacol. 104:29–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lien LM, Wang MJ, Chen RJ, Chiu HC, Wu JL,
Shen MY, Chou DS, Sheu JR, Lin KH and Lu WJ: Nobiletin, a
polymethoxylated flavone, inhibits glioma cell growth and migration
via arresting cell cycle and suppressing MAPK and Akt pathways.
Phytother Res. 30:214–221. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Safia Kamil M, Jadiya P, Sheikh S, Haque
E, Nazir A, Lakshmi V and Mir SS: The chromone alkaloid,
rohitukine, affords anti-cancer activity via modulating apoptosis
pathways in A549 cell line and yeast mitogen activated protein
kinase (MAPK) pathway. PLoS One. 10:e01379912015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Atiq R, Hertz R, Eldad S, Smeir E and
Bar-Tana J: Suppression of B-Raf(V600E) cancers by MAPK
hyper-activation. Oncotarget. 7:18694–18704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chakraborty C, Sharma AR, Patra BC,
Bhattacharya M, Sharma G and Lee SS: MicroRNAs mediated regulation
of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget.
7:42683–42697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li L, Wen XZ, Bu ZD, Cheng XJ, Xing XF,
Wang XH, Zhang LH, Guo T, Du H, Hu Y, et al: Paclitaxel enhances
tumoricidal potential of TRAIL via inhibition of MAPK in resistant
gastric cancer cells. Oncol Rep. 35:3009–3017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li QC, Liang Y, Tian Y and Hu GR:
Arctigenin induces apoptosis in colon cancer cells through
ROS/p38MAPK pathway. J BUON. 21:87–94. 2016.PubMed/NCBI
|
|
38
|
Lin L and Bivona TG: The Hippo effector
YAP regulates the response of cancer cells to MAPK pathway
inhibitors. Mol Cell Oncol. 3:e10214412015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dunn KL, Espino PS, Drobic B, He S and
Davie JR: The Ras-MAPK signal transduction pathway, cancer and
chromatin remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oka H, Chatani Y, Hoshino R, Ogawa O,
Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M and Yoshida O:
Constitutive activation of mitogen-activated protein (MAP) kinases
in human renal cell carcinoma. Cancer Res. 55:4182–4187.
1995.PubMed/NCBI
|
